UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Cancer, 2022-04, Vol.128 (8), p.1574-1583

2022

Volltextzugriff (PDF)

A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma

Internal medicine journal, 2024-03, Vol.54 (3), p.414-420

2024

Volltextzugriff (PDF)

The validity of progression‐free survival 2 as a surrogate trial end point for overall survival

Cancer, 2022-04, Vol.128 (7), p.1449-1457

2022

Volltextzugriff (PDF)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002255

2021

Volltextzugriff (PDF)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia

Frontiers in Urology, 2024-02, Vol.4

2024

Volltextzugriff (PDF)

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

Cancers, 2022-12, Vol.15 (1), p.254

2022

Volltextzugriff (PDF)

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

Journal of Gynecologic Oncology, 2019, 30(5), , pp.1-14

2019

Volltextzugriff (PDF)

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

The lancet oncology, 2020-09, Vol.21 (9), p.1213-1223

2020

Volltextzugriff (PDF)

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice

Journal of patient-reported outcomes, 2017-01, Vol.1 (1), p.5-5, Article 5

2017

Volltextzugriff (PDF)

Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed

International journal of gynecological cancer, 2017-07, Vol.27 (6), p.1274-1282

2017

Volltextzugriff (PDF)

Outcomes of extensive stage extrapulmonary small cell cancer

Internal medicine journal, 2023-09, Vol.53 (9), p.1556-1563

2023

Volltextzugriff (PDF)

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

Quality of life research, 2016-10, Vol.25 (10), p.2457-2465

2016

Volltextzugriff (PDF)

Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial

International journal of gynecological cancer, 2017-06, Vol.27 (5), p.1046-1050

2017

Volltextzugriff (PDF)

Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.14-18

2022

Volltextzugriff (PDF)

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis

Lung cancer (Amsterdam, Netherlands), 2021-04, Vol.154, p.113-117

2021

Volltextzugriff (PDF)

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis

JAMA network open, 2020-09, Vol.3 (9), p.e2011809-e2011809

2020

Volltextzugriff (PDF)

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

BMJ open, 2022-01, Vol.12 (1), p.e057663

2022

Volltextzugriff (PDF)

The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1516-1516

2021

Volltextzugriff (PDF)

Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6518-6518

2022

Volltextzugriff (PDF)

Dedifferentiated umbilical metastases from low grade endometrioid endometrial adenocarcinoma complicated by super-obesity: A case report

International journal of surgery case reports, 2023-07, Vol.108, p.108449, Article 108449

2023

Volltextzugriff (PDF)

Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis

Expert review of anticancer therapy, 2017-10, Vol.17 (10), p.965-979

2017

Volltextzugriff (PDF)

The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5604-5604

2023

Volltextzugriff (PDF)

Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8599-TPS8599

2023

Volltextzugriff (PDF)

DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8599-TPS8599

2022

Volltextzugriff (PDF)

713 The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A504-A504

2024

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(37)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Oncology
(15)
Humans
(13)
Randomized Controlled Trials As Topic
(7)
Female
(6)
Patients
(6)
Chemotherapy
(5)
Clinical Trials
(5)
Quality Of Life
(5)
Adult
(4)
Aged
(4)
General & Internal Medicine
(4)
Immunotherapy
(4)
Lung Neoplasms - Drug Therapy
(4)
Medicine, General & Internal
(4)
Middle Aged
(4)
Mutation
(4)
Survival
(4)
Tumors
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma

The validity of progression‐free survival 2 as a surrogate trial end point for overall survival

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice

Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed

Outcomes of extensive stage extrapulmonary small cell cancer

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial

Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors

Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer

Dedifferentiated umbilical metastases from low grade endometrioid endometrial adenocarcinoma complicated by super-obesity: A case report

Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis

The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)

Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)

DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial

713 The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)

Suchergebnisse filtern